TY - JOUR
T1 - Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice
AU - Broggini, M.
AU - Colombo, T.
AU - D'Incalci, M.
AU - et.al., [No Value]
PY - 1981
Y1 - 1981
N2 - Plasma pharmacokinetics of hexamethylmelamine (HMM) and pentamethylmelamine (PMM) were investigated after ip administration of doses of 50 or 100 mg/kg to M5076/73A ovarian tumor-bearing C75BL/6J female mice. The half-life of HMM was 44.5-49 mins; the half-life of PMM was 7.6-8.7 mins. The area under the concentration-versus-time curve (AUC) was also much higher for HMM than for PMM. The AUC for the metabolite N2, N2,N4,N6-tetramethylmelamine (TMM) was seven to ten times higher than that of the parent compounds. After incubation with mouse liver microsomes and cofactors, the rates of metabolism of HMM and PMM were essentially the same. Plasma protein binding was 94%, 71%and 50% for HMM, PMM, and TMM, respectively.
AB - Plasma pharmacokinetics of hexamethylmelamine (HMM) and pentamethylmelamine (PMM) were investigated after ip administration of doses of 50 or 100 mg/kg to M5076/73A ovarian tumor-bearing C75BL/6J female mice. The half-life of HMM was 44.5-49 mins; the half-life of PMM was 7.6-8.7 mins. The area under the concentration-versus-time curve (AUC) was also much higher for HMM than for PMM. The AUC for the metabolite N2, N2,N4,N6-tetramethylmelamine (TMM) was seven to ten times higher than that of the parent compounds. After incubation with mouse liver microsomes and cofactors, the rates of metabolism of HMM and PMM were essentially the same. Plasma protein binding was 94%, 71%and 50% for HMM, PMM, and TMM, respectively.
UR - http://www.scopus.com/inward/record.url?scp=0019521944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019521944&partnerID=8YFLogxK
M3 - Article
C2 - 6788370
AN - SCOPUS:0019521944
VL - 65
SP - 669
EP - 672
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
SN - 0361-5960
IS - 7-8
ER -